Oral supramolecular nanovectors for dual natural medicine codelivery to prevent gastric mucosal lesion

Abstract

Industrializable supramolecular nanovectors loaded with dual natural medicine were orally administered to prevent gastric mucosal lesion. The possible mechanisms were clarified.

M2 Macrophage Hybrid Membrane‐Camouflaged Targeted Biomimetic Nanosomes to Reprogram Inflammatory Microenvironment for Enhanced Enzyme‐Thermo‐Immunotherapy

“…A bioequivalence evaluation was further conducted (Figure 7H). [ 23 ] After intravenous administration, the URI and USM[H]L biometrics were not bioequivalent. The AUC (0‐72 h) 90% confidence interval of the logarithmic ratio of these two was 131.3–136.5% and not within the standard equivalent interval (80–125%).…”

Modulation of engineered nanomaterial interactions with organ barriers for enhanced drug transport

“…Nanovectors designed for dual encapsulation of evodiamine and curcumin drugs for the treatment of gastric mucosal lesions allowed for improved insight into how the drug formulations would interact in the GI environment in the presence of efflux pumps; this technology allowed researchers to estimate the absorption of the drugs in the supramolecular nanocomplex according to the epithelial cellular uptake models. 207 Similarly, to investigate the gastroprotective effect in a rat model, in silico response and contour plots have been used to optimize the globule size of self-nano emulsion particles, where the predicted sizes were similar to the actual value measured (67.7 nm calculated versus 64.8 nm actual). 208 Adding automation for the high throughput screening of nanoparticle formulations is necessary to improve optimization speed and predict biological interactions such as solubility and potential penetration capabilities.…”